Abstract
Reward-based motivations to eat seem to overpower homeostatic drives in some individuals. Binge eating represents an extreme phenotype of hedonic overeating, is a significant risk factor for substantial weight gain over time, and a defining symptom of both binge eating disorder (BED) and bulimia nervosa. Experts believe the action of the neurotransmitter dopamine on the brain’s “common reward pathway” is primarily accountable for hedonic motivations for food intake. The genetically determined action and availability of dopamine on this pathway appear to determine individual variations in the tendency to overeat and vulnerability to binge eating disorders and obesity. Some experts speculate dysfunctional dopamine availability predisposes individuals to binge eating based on the Reward Deficiency Syndrome theory of addictive behaviors; whereas, contrasting views propose an elevated dopamine signal also places individuals at risk for binge eating due to a stronger appetitive motivation and response to food cues and eating. Dopamine availability is polygenic and determined by several factors, one of which is the density of dopamine transporter (DAT) – which regulates the strength and duration of the dopamine signal by transporting it back into the presynaptic neuron. The gene encoding the DAT protein has been of particular interest in studies on addictions and eating behavior, as it contains a functional VNTR polymorphism. Variations of the DAT gene (DAT1) VNTR are associated with differences in DAT-binding site density, and therefore, levels of dopamine availability. This chapter reviews the literature on the role of the DAT1 in obesity and binge eating disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD(H)D:
-
Attention deficit/(hyperactivity) disorder
- BED:
-
Binge eating disorder
- BMI:
-
Body mass index
- DAT:
-
Dopamine transporter
- DAT1:
-
Dopamine transporter gene
- DSM-IV-TR:
-
Diagnostic Statistical Manual of Mental Disorders – Fourth Edition
- RDS:
-
Reward deficiency syndrome
- UTR:
-
Untranslated region
- VNTR:
-
Variable number tandem repeat
References
Agranat-Meged AN, Deitcher C, Goldzweig G, Leibenson L, Stein M, Galili-Weisstub E. Int J Eat Disord. 2005;37:357–9.
Altfas JR. BMC Psychiatry. 2002;2:9.
American Psychiatric Association. Diagnostic and statistical manual. 4th ed. Text revision. Washington, DC: American Psychiatric Association Press; 2000.
Bellgrove MA, Hawi Z, Kirley A, Fitzgerald M, Gill M, Robertson IH. Neuropsychopharmacology. 2005;30:2290–7.
Berridge KC. Brain Cogn. 2003;52:106–28.
Bina KG, Cincotta AH. Neuroendocrinology. 2000;71:68–78.
Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE. J Psychoactive Drugs. 2000;32 (Suppl. i–iv):1–112.
Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE. J R Soc Med. 1996;89:396–400.
Bulik CM, Sullivan PF, Kendler KS. Int J Eat Disord. 2003;33:293–8.
Chen PS, Yang YK, Yeh TL, Lee I-H, Yao WJ, Chiu NT, Lu RB. NeuroImage. 2008;40(1):275–9.
Cochrane C, Malcolm R, Brewerton T. Addict Behav. 1998;23:201–7.
Cragg SJ, Rice ME. Trends Neurosci. 2004;27:270–7.
Crits-Christoph P, Newberg A, Wintering N, Ploessl K, Gibbons MB, Ring-Kurtz S, Gallop R, Present J. Drug Alcohol Depend. 2008;98:70–6.
Cummings DE, Schwartz MW. Annu Rev Med. 2003;54:453–71.
Davis C, Fox J. Appetite. 2008;50:43–9.
Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C, Patte K, Hwang R, Kennedy JL. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:620–8.
Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C, Patte K, Kennedy JL. Neuropsychopharmacology 2007;32:2199–206.
Davis C, Levitan RD, Smith M, Tweed S, Curtis C. Eat Behav. 2006;7:266–74.
Davis C, Strachan S, Berkson M. Appetite. 2004;42:131–8.
Depue RA, Collins PF. Behavioral and Brain Sciences. 1999;22:491–569.
Epstein LH, Jaroni JL, Paluch RA, Leddy JJ, Vahue HE, Hawk L, Wileyto EP, Shields PG, Lerman C. Obes Res. 2002;10:1232–40.
Epstein LH, Temple JL, Neaderhiser BJ, Salis RJ, Erbe RW, Leddy JJ. Behav Neurosci. 2007;121:877–86.
Epstein LH, Wright SM, Paluch RA, Leddy JJ, Hawk LW, Jr., Jaroni JL, Saad FG, Crystal-Mansour S, Shields PG, Lerman C. Am J Clin Nutr. 2004;80:82–8.
Fairburn CG, Cooper Z, Doll HA, Norman P, O’Connor M. Arch Gen Psychiatry. 2000;57:659–65.
Franken IH, Muris P. Appetite. 2005;45:198–201.
Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. Pharmacogenomics J. 2001;1:152–6.
Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG. Mol Pharmacol. 1992;42:383–90.
Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR. Neuropsychopharmacology. 2000;22:133–9.
Hernandez L, Hoebel BG. Brain Res Bull. 1990;25:975–9.
Jeffery RW, Utter J. Obes Res. 2003;11 (Suppl.):12S–22S.
Jorm AF, Henderson AS, Jacomb PA, Christensen H, Korten AE, Rodgers B, Tan X, Easteal S. Am J Med Genet. 2000;96:331–4.
Kelley AE, Schiltz CA, Landry CF. Physiol Behav. 2005;86:11–4.
Koob GF. Trends in Pharmacological Science. 1992;13:177–84.
Kuo DY. J Biomed Sci. 2002;9:126–32.
Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS, Lerman C. Obes Res. 2004;12:224–32.
Li LB, Chen N, Ramamoorthy S, Chi L, Cui XN, Wang LC, et al. J Biol Chem. 2004;279:21012–20.
Mattos P, Saboya E, Ayrao V, Segenreich D, Duchesne M, Coutinho G. Rev Bras Psiquiatr. 2004;26:248–50.
Mill J, Asherson P, Browes C, D’Souza U, Craig I. Am J Med Genet. 2002;114:975–9.
Need AC, Ahmadi KR, Spector TD, Goldstein DB. Ann Hum Genet. 2006;70:293–303.
Nestle M. J Am Diet Assoc. 2003;103:39–40.
Neumark-Sztainer D, Story M, Resnick MD, Garwick A, Blum RW. Arch Pediatr Adolesc Med. 1995;149:1330–5.
Nicola SM, Taha SA, Kim SW, Fields HL. Neuroscience. 2005;135:1025–33.
Peters JC. Obes Res. 2003;11 (Suppl.):7S–11S.
Reichborn-Kjennerud T, Bulik CM, Tambs K, Harris JR. Int J Eat Disord. 2004;36:307–14.
Rucker D, Padwal R, Li SK, Curioni C, Lau DC. BMJ. 2007;335:1194–9.
Saelens BE, Epstein LH. Appetite. 1996;27:41–50.
Sander T, Harms H, Podschus J, Finckh U, Nickel B, Rolfs A, Rommelspacher H, Schmidt LG. Biol Psychiatry. 1997;41:299–304.
Saper CB, Chou TC, Elmquist JK. Neuron. 2002;36:199–211.
Shinohara M, Mizushima H, Hirano M, Shioe K, Nakazawa M, Hiejima Y, Ono Y, Kanba S. J Psychiatry Neurosci. 2004;29:134–7.
Stice E, Akutagawa D, Gaggar A, Agras WS. Int J Eat Disord. 2000;27:218–29.
Striegel-Moore RH, Franko DL. Int J Eat Disord. 2003;34 (Suppl.):S19–29.
Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. Genomics. 1992;14:1104–6.
VanNess SH, Owens MJ, Kilts CD. BMC Genet. 2005;6:55.
Volkow ND, Wang G-J, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding Y-S, Pappas N. American Journal of Psychiatry. 1999;156:1440–3.
Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, Ding YS, Gatley SJ, Gifford A, Zhu W, Swanson JM. Synapse. 2002;43:181–7.
Wang GJ, Volkow ND, Thanos PK, Fowler JS. J Addict Dis. 2004;23:39–53.
Wellman PJ. Curr Drug Targets. 2005;6:191–9.
Yang B, Chan RC, Jing J, Li T, Sham P, Chen RY. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:541–50.
Yanovski SZ. Int J Eat Disord. 2003;34 (Suppl.):S117–20.
Yun IA, Wakabayashi KT, Fields HL, Nicola SM. J Neurosci. 2004;24:2923–33.
Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA. J Neurosci. 2006;26:4901–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wight, K., Reid-Westoby, C., Davis, C. (2011). The Dopamine Transporter Gene (DAT1) in Obesity and Binge Eating Disorders. In: Preedy, V., Watson, R., Martin, C. (eds) Handbook of Behavior, Food and Nutrition. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92271-3_168
Download citation
DOI: https://doi.org/10.1007/978-0-387-92271-3_168
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-92270-6
Online ISBN: 978-0-387-92271-3
eBook Packages: MedicineMedicine (R0)